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Abstract
Background: Domains are basic units of proteins, and thus exploring associations between protein domains and
human inherited diseases will greatly improve our understanding of the pathogenesis of human complex diseases
and further benefit the medical prevention, diagnosis and treatment of these diseases. Within a given domaindomain interaction network, we make the assumption that similarities of disease phenotypes can be explained
using proximities of domains associated with such diseases. Based on this assumption, we propose a Bayesian
regression approach named “domainRBF“ (domain Rank with Bayes Factor) to prioritize candidate domains for
human complex diseases.
Results: Using a compiled dataset containing 1,614 associations between 671 domains and 1,145 disease
phenotypes, we demonstrate the effectiveness of the proposed approach through three large-scale leave-one-out
cross-validation experiments (random control, simulated linkage interval, and genome-wide scan), and we do so in
terms of three criteria (precision, mean rank ratio, and AUC score). We further show that the proposed approach is
robust to the parameters involved and the underlying domain-domain interaction network through a series of
permutation tests. Once having assessed the validity of this approach, we show the possibility of ab initio inference
of domain-disease associations and gene-disease associations, and we illustrate the strong agreement between our
inferences and the evidences from genome-wide association studies for four common diseases (type 1 diabetes,
type 2 diabetes, Crohn’s disease, and breast cancer). Finally, we provide a pre-calculated genome-wide landscape
of associations between 5,490 protein domains and 5,080 human diseases and offer free access to this resource.
Conclusions: The proposed approach effectively ranks susceptible domains among the top of the candidates, and
it is robust to the parameters involved. The ab initio inference of domain-disease associations shows strong
agreement with the evidence provided by genome-wide association studies. The predicted landscape provides a
comprehensive understanding of associations between domains and human diseases.

Background
Over the past few decades, remarkable success has been
achieved for such traditional gene-mapping approaches
as family-based linkage analysis [1,2] and populationbased association studies [3,4] in pinpointing genes that
are responsible for human inherited diseases [5,6].
Nevertheless, these traditional methods are either only
capable of linking diseases with genetic regions that
typically contain dozens to hundreds of genes, or usually
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require carefully selected candidate genes that are biologically related to the disease under investigation [5,6].
Consequently, the development of computational methods for the inference of genes and their protein products
that are truly responsible for the disease of interest has
been one of the major tasks in human genetics and
functional genomics [7-18]. Particularly, a protein typically consists of several structural domains, each of
which is closely related to a specific function of the protein. Therefore, the inference of causative genes could
be aided by first dividing products of candidate genes
into discrete domains with known functions and structural features and then infer the association of these

© 2011 Zhang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.

Zhang et al. BMC Systems Biology 2011, 5:55
http://www.biomedcentral.com/1752-0509/5/55

domains to the disease of interest [19-21]. Following this
direction, a new protein domain called PAAD has been
discovered to be associated with apoptosis, cancer, and
autoimmune diseases [19], and a novel domain called
G8 has been reported to be linked to polycystic kidney
disease and non-syndromic hearing loss [20]. However,
most of these discoveries have thus far been made with
the assistance of protein sequence analysis and other
experimental techniques. Even though such findings are
significant, the associations reported are still very sporadic. Therefore, it would be helpful to develop computational methods to directly infer possible associations
between domains and human diseases.
It has been shown that deleterious nonsynonymous
single nucleotide polymorphisms (nsSNPs) that are
responsible for a specific disease of interest may change
structures of some protein domains, affect functions of
corresponding proteins, and further result in the disease
under investigation. Therefore, existing associations
between domains and diseases can be constructed by
bridging protein domains that contain known deleterious nsSNPs and human diseases with which the
nsSNPs are associated [22]. Furthermore, recent
advances in computational functional genomics have
enabled the large-scale prediction of domain-domain
interactions and have led to repositories of known and
predicted domain-domain interactions such as DOMINE
[23] and InterDom [24,25]. Accordingly, large-scale
inference of unknown associations between domains
and human diseases can be performed by using these
data sources. For example, one of our previous studies
[22] adopted the “guilt-by-association” principle [26] to
compute scores that quantify the strength of associations between a query disease and candidate domains
from domain-domain interaction data and known associations between the query disease and other domains,
and then rank candidate domains according to their
scores. However, the scope of application of this
approach is limited because the “guilt-by-association”
principle relies on known associations between the
query disease and domains to infer novel associations
for the query disease. Under these conditions, the
method cannot be applied to diseases whose genetic
bases are completely unknown.
Recent studies on the modular nature of human
genetic diseases have shown that diseases share common
clinical characteristics are often caused by functionally
related genes [16,27]. With the application of text
mining techniques, it has also been possible to calculate
pair-wise similarities for most human disease phenotypes [28]. With these advances, various methods have
been proposed to prioritize candidate genes through the
combined use of disease phenotype similarity and gene
proximity [7,8,29-32]. Inspired by the successes of these
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methods, we propose in this paper to infer associations
between domains and human disease phenotypes based
on the assumption that phenotypically similar diseases
are caused by functionally related domains. More specifically, we resort to a linear regression framework to
model the relationship between a domain proximity profile and a phenotype similarity profile, and we develop a
Bayesian regression approach, called domainRBF
(domain Ranking with Bayes Factor), to calculate Bayes
factors that quantify the strength of associations
between corresponding domain proximity profiles and
phenotype similarity profiles.
We compile a set of known domain-disease associations using the Pfam database [33] and annotations of
nsSNPs in the UniProt database [34,35], extract a
domain-domain interaction network from the DOMINE
database [23] as well as the InterDom database [24,25],
and then download a pre-calculated phenotype similarity
network [28]. Using these data, we show that domain
proximities calculated from a domain-domain interaction network do, indeed, imply phenotype similarities of
diseases. We next validate the approach and evaluate its
performance using three criteria: precision, mean rank
ratio, and AUC score. To accomplish this, we apply
three large-scale leave-one-out cross-validation experiments against random control, simulated linkage interval, and genome-wide scan with two domain proximity
measures: diffusion kernel and shortest path with Gaussian kernel. Results show that the proposed approach
can successfully recover known associations between
domains and human diseases. We further show the
robustness of this approach to the parameters involved
and the underlying domain-domain interaction network
through a series of permutation tests. Having successfully assessed the validity and robustness of this
approach, we can then infer domain-disease in an ab
initio way and illustrate the strong agreement of the
inference results with evidence of genome-wide association studies for four common human diseases, including
type 1 diabetes, type 2 diabetes, Crohn’s disease, and
breast cancer. We further demonstrate the possibility of
inferring gene-disease associations from domain-disease
associations. Finally, we calculate a genome-wide landscape of associations between 5,490 domains and 5,080
human diseases using all known domain-disease associations, and we provide a freely accessible website for this
resource.

Methods
Overview of the DomainRBF approach

We ground the inference of domains that are associated
with human inherited diseases on a set of known
domain-disease associations that are compiled from the
Pfam database [33] and annotations of nsSNPs in the
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UniProt database [34,35], a domain-domain interaction
network extracted from the DOMINE database [23] and
the InterDom database [24,25], as well as a pre-calculated phenotype similarity network containing pair-wise
similarity scores among more than 5,000 human genetic
disease phenotypes in the OMIM database [28].
Based on the assumption that phenotypically similar
diseases are caused by functionally related domains, we
propose a linear regression framework to model the
relationship between a domain proximity profile and a
phenotype similarity profile, and we resort to a Bayesian
approach to solve the linear regression model. As shown
in Figure 1 (inspired by Ideker and Sharan [36]), given a
query phenotype p and the pre-calculated pair-wise
similarity scores between phenotypes, we extract scores
between the query phenotype and all other phenotypes
that have at least one associated domain and obtain a
phenotype similarity profile for the query phenotype.
On the other hand, for a query domain d in a set of
candidate domains, we resort to the domain-domain
interaction network to calculate proximity scores of the
query domain to all domains that are known to be associated with some phenotypes and further calculate a
domain proximity profile. With these two profiles, we
propose a Bayesian regression approach called
domainRBF (domain Ranking with Bayes Factor) to calculate a Bayes factor that quantifies the strength of association between the query domain and the query
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phenotype, using the phenotype similarity profile as the
response variable and the domain proximity profile as
the predictor variable. Finally, we rank candidate
domains according to their corresponding Bayes factors
and obtain a rank list of the candidates.
Data sources
Domain-disease associations

A domain is defined as associated with a disease if the
domain contains at least one nonsynonymous single
nucleotide polymorphism (nsSNP) associated with the
disease [22]. Therefore, associations between domains
and diseases are obtained by combining known associations between nsSNPs and diseases as well as relationships between protein and domains.
Known associations between nsSNPs and diseases
are obtained from annotations of nsSNPs in the UniProt database [34,35], in which nsSNPs are classified
into three categories: disease, polymorphism, and
unclassified. In version 57.15 (released on March 2,
2010) of this database, 23,372 nsSNPs belong to the
disease category, 36,303 belong to the polymorphism
category, and the remaining 2,019 nsSNPs are currently unclassified. For each of the nsSNPs in the disease category, the entry ID of the specific disease in
the OMIM database is also provided. Consequently,
we obtain 19,552 associations between 19,552 nsSNPs
and 1,592 diseases.

Figure 1 Scheme of the proposed domainRBF approach. Texts in addition to pink arrows denote the pipeline of the domainRBF approach.

Zhang et al. BMC Systems Biology 2011, 5:55
http://www.biomedcentral.com/1752-0509/5/55

Relationships between human proteins and domains
are obtained from the Pfam database [33], which provides a large collection of both high quality protein
domain families (Pfam-A) and low quality protein
domain families (Pfam-B). In version 24.0 of the Pfam-A
collection (released in October 2009), 11,912 domain
families that cover more than 75.15% of known proteins
are collected. Using this data source, we obtain 96,276
relationships between 4,324 domains and 66,498 human
proteins.
Using the above data sources and having defined a
domain as associated with a disease if the domain contains at least one nsSNP associated with the disease, we
are able to establish 1,614 associations between 671
domains and 1,145 diseases.
Domain-domain interaction networks

Our inference of domain-disease associations is based
on domain-domain interaction networks extracted from
the DOMINE [23] and InterDom [24,25], two of the
most widely-used databases of known and predicted
domain-domain interactions.
The latest version of DOMINE (released in February
2008) contains a total of 20,513 domain-domain interactions, out of which 4,349 (gold-standard positives) are
inferred from PDB entries (the union of the sets of
interactions from iPfam [37] and 3did [38,39]), and
17,781 are predicted by at least one computational
approach of 8 different computational approaches using
Pfam domain definitions. Of the 17,781 predicted interactions, there are 3,143 high-confidence predictions
(predicted by ME [40] or at least two different
approaches), 729 medium-confidence predictions (hetero-domain interactions in which both domains have
the same annotations in the biological process of the
gene ontology), and 13,909 remaining low-confidence
predictions [23].
The latest version of InterDom (released in July 31,
2007) contains a total of 148,938 domain-domain interactions, out of which 7,718 are inferred from PDB
entries [41], 143,820 are inferred from BIND [42] and
DIP [43] entries, and 4,631 are inferred from the
domain fusion hypothesis. InterDom further uses a
probabilistic scoring system to give confidence scores to
domain interactions that are derived independently by
multiple methods from different data sources. Finally,
interactions with 90%, 75%, 50%, and 25% confidence
levels are provided [24,25].
In our work, we use two domain-domain interaction
networks extracted from these data. First, we discard
singletons in the PDB part of the DOMINE database
[23] and obtain a small network that is composed of
2,285 interactions between 1,971 domains (2.32 interactions per domain on average). Second, we combine
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37,177 interactions whose confidence scores are at least
90% in the InterDom database and all interactions in
the DOMINE databases to obtain a large domaindomain interaction network that is composed of 48,778
interactions between 5,490 domains (17.77 interactions
per domain on average).
The phenotype similarity network

The phenotype similarity network of human diseases is
a fully connected network obtained from an earlier
work of van Driel et al. [28], in which the pair-wise
relationships between 5,080 human genetic diseases
from the OMIM database are mapped. Briefly, van
Driel et al. use the anatomy (A) and the disease (C)
sections of the medical subject headings vocabulary
(MeSH) to extract terms from the OMIM database,
thus providing a standard way of presenting the
OMIM records as corresponding phenotype feature
vectors. As a result, each disease phenotype is characterized by a vector of standardized and weighted phenotypic feature terms mapped from corresponding
OMIM records in the full text (TX) and clinical synopsis (CS) fields. Then, for each pair of disease phenotypes, a similarity score is calculated by the cosine of
their feature vector angle. The reliability of the phenotype similarity score has been tested [28], showing that
these similarities are positively correlated with a number of measures of gene functions. The final phenotype
similarity network contains pair-wise similarity scores
for 5,080 OMIM records, covering a majority of
recorded human disease phenotypes.
The DomainRBF model

Given the phenotype similarity network, we use ypp’ to
denote the similarity score between a query disease phenotype p and another disease phenotype p’. We further
define the phenotype similarity profile for disease phenotype p as yp = (ypp1 , ypp2 , · · · , yppm )T , i.e., the similarities between the disease phenotype p and all m disease
phenotypes p 1 , p 2 , ..., p m that have at least one associated domain.
On the other hand, given a domain-domain interaction network of n nodes, we calculate the proximity
between two domains using two measures: (1) shortest
path with Gaussian kernel (SG) and (2) diffusion kernel
(DK). The shortest path proximity between two domains
u and v, SP(u,v), is defined as the length of the shortest
path between the two domains. Using the Gaussian kernel, the proximity distance measure SG (u, v) is obtained
as SG(u,v) = exp{-b(SP(u,v))2}, where b is a free parameter. The diffusion kernel for the network is defined
as K = (k uv ) n×n = e -gL , where 0 < g < 1 is a free parameter that controls the magnitude of diffusion. The
matrix L = D - A is the Laplacian of the network, where
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D is a diagonal matrix containing node degrees, and A
is the adjacency matrix of the domain-domain interaction network. With the diffusion kernel K = (kuv)n×n, we
define the diffusion proximity of two domains u and v
as DK(u,v) = kuv, i.e., the corresponding element in the
diffusion kernel. Then, let x dd’ denote the proximity
between domains d and d’ in the domain-domain interaction network, and let D(p) denote the set of domains
known to be associated with a phenotype p. We define
the proximity between domain d to disease phenotype p
as the summation of proximity scores between domain
d and all domains known to be associated with disease
phenotype p, i.e., xdp = ∑d’ÎD(p) xdd’. We further define
the domain proximity profile for domain d as
xd = (xdp1 , xdp2 , · · · , xdpm )T .
Then, given a query disease phenotype p and a query
domain d, we explain the phenotype similarity profile yp
using domain proximity profile xd via a linear regression
model
y = Xβ + ε

where y = y p is the response vector, X = (1,xd ) the
design matrix, b = (b0, b1)T the coefficient vector, and
ε = (ε1 ,..., ε m)T the residual vector. Note that the first
column of the design matrix being 1s for the purpose
of incorporating the intercept. We propose to solve
this linear regression model using a Bayesian
approach. We choose to take a Bayesian approach
because it provides a natural way to consider the
uncertainty in estimated parameters, and it provides
Bayes factor, a measure of the strength of evidence for
an association, which is defined as the ratio of marginal likelihoods for y conditional on X under the
alternative and the null hypothesis, respectively, as
described below.
For the alternative model, we assume that y conditional on X is subject to a normal distribution, as
y|X, β, σ 2 ∼ Normal(Xβ, σ 2 I),

with residuals independent and identically distributed,
following normal density with mean 0 and variance s2.
We set conjugate prior distributions for b and s2, as
σ 2 ∼ Inverse - χ 2 (n0 , σ02 ),

and
β|σ 2 ∼ Normal(μ0 , σ 2  0 ),

where μ0 = (μ0, μ1)T is composed of prior means, and
s Σ 0 prior variances with Σ 0 = diag(s μ 2 ,s 1 2 ) being a
diagonal matrix. The joint distribution of all random
quantities y, b, and s2 is then given as
2
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p(y, β, σ 2 |X)
=p(y|X, β, σ 2 )p(β|σ 2 , μ0 ,  0 )p(σ 2 |n0 , σ02 )


n/2

yT y − 2yT Xβ + β T XT Xβ
1
exp
−
×
=
2π σ 2
2σ 2


1/2

T −1
T −1
β T  −1
1
0 β − 2β 0 μ0 + μ0  0 μ0
exp
−
×
2π σ 2 | 0 |
2σ 2



n /2 
1 n0 /2+1
(n0 σ02 ) 0
n0 σ02
.
exp
−
(n0 /2) σ 2
2σ 2

Integrating out b and s2, we obtain the marginal likelihood of y given X as

p1 (y|X) =

1
2π

n/2 

| n |
| 0 |

1/2

n /2

(nn /2) (n0 σ02 ) 0
,
(n0 /2) (nn σn2 )nn /2

where nn = n + n0 and nn sn2 = n0s02 + yTy + μ0T Σ0μ0-μnT Σn-1μn with Σn = (XT X + Σ0-1)-1 and μn = Σn
(XT y + Σ0-1μ0).
On the other hand, for the null model, where y is
independent of X, the marginal likelihood of y can be
derived in a similar way, as
1


p0 (y) =

1
2π

n/2 

n
0

1/2

n /2

(nn /2) (n0 σ02 ) 0
,
(n0 /2) (nn σ̃n2 )nn /2

where
0 = σμ2 , n = (n + 1/σμ2 )−1 , nn σ̃n2 = n0 σ02 + yT y + μ20 /σμ2 − (n + 1/σμ2 )−1 (nȳ + μ0 /σμ2 )2,

1 m
yi.
i=1
m
Then, the Bayes factor BF is the ratio of p1(y|X) and
p0(y), as

and ȳ =

BF =

p1 (y|X)
=
p0 (y)



| n |
n

1/2 

| 0 |
0

−1/2 

nn σn2
nn σ̃n2

−nn /2
.

Following the literature [44], we take the limit +∞ for
sμ2 and 0 for both n0 and s02, and we obtain the limit
value of the Bayes factor as
BFlim =


n/2
(n| n |)1/2
yT y − nȳ2
.
T
σ1
yT y − μTn  −1
n μn

For simplicity, we further set μ0 = 0 as in the literature [44], and we set s12 = 1 as the default setting in
this paper, although the effect of these parameters are
also studied.
Note that before the construction of the Bayesian
regression relationship between yp and xd, we apply an
inverse-normal transform to y p to guarantee that the
responsive variable is normally distributed. As illustrated
in [45,46], the transform formula we use is:
yi = −1 (ri /(m + 1)), for i = 1, . . . , m
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where r i is the rank of yppi in the vector y p , m the
length of yp, and F the cumulative distribution function
of the standard normal distribution.
Validation methods and evaluation criteria

On the basis of the domain-domain interaction network
and known associations between protein domains and
disease phenotypes, we proceed to validate how well the
proposed approach performs in recovering these known
associations. We adopt three large scale leave-one-out
cross-validation experiments for this purpose.
First, in the validation of random controls, we prioritize domains that are known to be associated with disease phenotypes (i.e., disease domains) against randomly
selected control domains. Specifically, in each run of the
validation, we select an association between a domain
and a disease phenotype, assume that the association is
unknown, and prioritize the domain against a set of 99
randomly selected control domains.
Second, in the validation of simulated linkage intervals, we prioritize domains that are known to be associated with disease phenotypes (i.e., seed domains)
against domains that are located around the seed
domains. Specifically, in each run of the validation, we
select an association between a domain and a disease
phenotype, assume that the association is unknown, and
prioritize the domain against a set of control domains
that are located within 10 Mbp upstream and downstream of this domain.
Third, in the validation of genome-wide scan, we
prioritize seed domains against all known domains. Specifically, in each run of the validation, we select an association between a domain and a disease phenotype,
assume that the association is unknown, and prioritize
the domain against all other domains in the domaindomain interaction network.
In each of the above leave-one-out cross-validation
experiments, we repeat the validation run for every
known association between a domain and a disease phenotype, and we are able to obtain a number of ranking
lists. We further normalize the ranks by dividing them
by the total number of candidate domains in the rankling list to obtain rank ratios and calculate the values of
three criteria to measure the performance of a prioritization method.
The first criterion is termed precision. We consider a
prediction as successful if the known disease domain is
ranked at the top (with rank 1). Then, the proportion of
successful predictions among all predictions is defined
as the precision. Obviously, a high precision suggests
that a method has high prediction power. The second
criterion is termed mean rank ratio, which is simply the
average of rank ratios for all known disease domains in
a cross-validation experiment. This criterion provides a
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summary of the ranks of all domains that are known to
be associated with disease phenotypes, and the smaller
the mean rank ratio, the better a method. The third criterion is termed AUC, which is the area under the receiver operating characteristic curve (ROC). Given a list of
rank ratios and a predefined threshold, we define the
sensitivity as the percentage of disease domains that are
ranked above the threshold and the specificity as the
percentage of control domains that are ranked below
the threshold. By varying the threshold values, we are
able to plot a receiver operating characteristic curve,
which shows the relationship between sensitivity and 1specificity. Calculating the area under the ROC curve
(AUC), we are able to obtain the AUC score, which provides an overall measure for the performance of the
prioritization approach.

Results
Domain proximity implying phenotype similarity

The DomainRBF approach is based on the assumption
that similarities of disease phenotypes can be explained
by proximities of domains associated with the phenotypes within a domain-domain interaction network via a
regression model. In order to validate this assumption,
we discard singletons in the PDB part of the DOMINE
database [23] and obtain a domain-domain interaction
network that is composed of 2,285 interactions between
1,971 domains. Focusing on these domains, we obtain
1,066 associations between 763 phenotypes and 378
domains. Then, we calculate a Bayes factor for each of
these associations, and run a Wilcoxon signed rank test
to check whether the resulting Bayes factors are significantly greater than 1 (the random case). Results show
that the p-value is smaller than 2.2 × 10-16, indicating
that the similarities of disease phenotypes have a strong
relationship with the proximities of associated domains.
To further substantiate this point, we perform a series
of permutations towards disease-disease, domain-disease, and domain-domain relationships. First, we break
the disease-disease relationship by permuting the phenotype similarity profile. Second, we break the domain-disease relationship by two methods: (1) permuting
domain-disease associations and (2) replacing domains
in known disease-domain associations with randomly
selected domains. Third, we break the domain-domain
relationship by permuting connections in the underlying
domain-domain interaction network, while keeping node
degrees and recalculating the diffusion kernel. For each
of the above permutations, we calculate Bayes factors of
disease domains and present the results in Figure 2,
which shows that the median of Bayes factors based on
the original data is much higher than the medians
obtained from the different permuted relationships, as
described above.
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Figure 2 Bayes factors of the original and permuted data. “original”, “permuted PPS”, “permuted seed”, “random seed”, and “permuted DDI”
denote the results obtained using the original data, permuted phenotype similarity profile, permuted domain-disease associations, randomly
selected seed domains, and permuted domain-domain interaction network, respectively. The small domain-domain interaction network
composed of the PDB part of the DOMINE database and the diffusion kernel are used to obtain the results.

We also perform similar studies using the large
domain-domain interaction network (48,778 interactions
between 5,490 domains) that includes the entire DOMINE database [21] and the high-confidence part of the
InterDom [22,23] database. Results show that Bayes factors for known domain-disease associations are also significantly greater than 1, while the p-value of the
Wilcoxon signed rank test is smaller than 2.2 × 10-16.
We further perform a series of permutation tests and
present the results [Additional file 1: Supplemental Figure S1]. Based on these comprehensive studies, our
hypothesis has been clearly demonstrated: that similarities between diseases can be explained by the proximities of domains associated with such diseases within a
given domain-domain interaction network. In other
words, domain proximity implies phenotype similarity.
Performance of the DomainRBF approach

Since interactions from the PDB entries have the highest
confidence of domain-domain interactions, we first test
the validity of our approach on the PDB part of the
DOMINEdatabase [23]. We implement three large-scale
leave-one-out cross-validation experiments against random controls, simulated linkage intervals and genomewide scan, respectively, each on the basis of two distance measures: diffusion kernel (DK) and shortest path
with Gaussian kernel (SG).
For each of the three validation experiments, using
either the diffusion kernel or the shortest path with
Gaussian kernel, we draw a histogram of rank ratios for
the entire 1,066 known associations, as shown in Figure
3. From the figure we see that rank ratios are concentrated mostly within the interval of the first few bins,
and as the rank ratios increase, corresponding

frequencies all take a general trend of declination. In
other words, the proposed approach is capable of ranking domains known as associated with some disease
phenotypes among the top of the candidates.
We then assess the performance of the proposed
approach using the three criteria (mean rank ratio, precision, and AUC score) and summarize the results in
Table 1. First, we can see from these results that the
domainRBF approach can successfully recover the associations between protein domains and human disease
phenotypes. For example, in the cross-validation for random controls, the precisions are greater than 26%, the
mean rank ratios are less than 12%, and the AUC scores
are greater than 88%. In the cross-validation for linkage
intervals, the precisions are greater than 23%, the mean
rank ratios are less than 12%, and the AUC scores are
greater than 89%. In the cross-validation for genomewide scan, the precisions are greater than 5%, the mean
rank ratios are less than 12%, and the AUC scores are
greater than 88%. We therefore conclude that the
domainRBF approach is effective in the identification of
domains that are associated with human disease
phenotypes.
Second, we conjecture from these results that the diffusion kernel measure is slightly better than the shortest
path measure with Gaussian kernel, because the mean
rank ratios obtained using the diffusion kernel are in
general smaller, and the precisions and AUC scores are
in general larger, than those obtained using the shortest
path with Gaussian kernel. This phenomenon might be
explained by the fact that diffusion kernel is a global
network-distance measure. As such, the distance
between two domains not only depends on the relative
location of the candidate domain to all other domains
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Figure 3 Histograms of rank ratios for domains known to be associated with diseases. (A) Results for shortest path with Gaussian kernel,
against random controls. (B) Results for shortest path with Gaussian kernel, against linkage intervals. (C) Results for shortest path with Gaussian
kernel, against genome-wide scan. (D) Results for diffusion kernel, against random controls. (E) Results for diffusion kernel, against linkage
intervals. (F) Results for diffusion kernels, against genome-wide scan. The small domain-domain interaction network composed of the PDB part of
the DOMINE database and the diffusion kernel are used to obtain the results.

(as the shortest path with Gaussian kernel does), but
also relies on the graph structure of the entire network.
Thus, for interaction networks with different graph
structure, two nodes with the same shortest path distance usually have different diffusion kernel distance,
and it is possible that this difference makes the diffusion
kernel distance more reasonable and precise in the
description of similarities between two domains in the
interaction network. This point has also been explicitly
illustrated in literature [29].

Third, we conjecture from these results that the
domainRBF approach with some proper defined priors
can achieve higher performance than the non-Bayesian
linear regression method. We compare the performance of the (Bayesian) domainRBF approach with the
(non-Bayesian) ordinary linear regression method
through the three large-scale leave-one-out cross-validation experiments, and we also list the results in
Table 1. Although both approaches can successfully
recover the associations between protein domains and

Table 1 Results of leave-one-out cross-validation experiments on the small network.

Precision

Random Control (%)

Linkage Interval (%)

R2

BF

R2

BF

Genome-wide Scan(%)
R2

BF

SG

26.11 (0.66)

26.56 (0.85)

21.69

23.79

6.29

5.25

DK

26.25 (0.63)

28.67 (0.72)

19.60

31.20

7.13

5.53

Mean Rank Ratio

SG

17.31 (0.11)

11.99 (0.05)

18.24

11.19

16.49

11.17

AUC

DK
SG

17.82 (0.13)
83.51 (0.10)

10.75 (0.09)
88.80 (0.05)

19.09
82.81

9.73
89.94

17.03
83.60

9.91
88.85

DK

83.01 (0.12)

90.04 (0.11)

81.95

90.18

83.06

90.11

The small network indicates the domain-domain interaction network that is composed of the PDB part of the DOMINE database. R denotes the ordinary nonBayesian linear regression approach (using R-square as scores for candidate domains). BF denotes the domainRBF approach (using Bayes factors as scores for
candidate domains). SG denotes shortest path with Gaussian kernel. DK denotes diffusion kernel. Results for random controls are mean (standard deviation) of 10
validation runs.
2
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human disease phenotypes, the results show that the
domainRBF approach can achieve better performance
than the ordinary linear regression approach in most
cases. For example, in all three cross-validation experiments, the domainRBF approach can achieve higher
precisions (with only two exceptions for genome-wide
scan), smaller mean rank ratios (for at least 5.32%),
and larger AUC scores (for at least 3.19%). When looking at the ROC curves (Figure 4), we see that the curve
of the domainRBF approach climbs much faster
towards the upper left corner of the plot than does
that of the ordinary linear regression approach, suggesting that the Bayesian domainRBF approach is
superior to the non-Bayesian ordinary linear regression
method.
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Robustness of the DomainRBF approach
Effects of network interactions

The above validation results suggest that the domainRBF
approach can successfully prioritize candidate domains
and put the domain that is truly associated with the
query disease phenotype at the top of the candidates.
However, it is still necessary to determine whether the
correct prioritization of disease domains is due to the
connectivity information that includes in the domaindomain interactions, domain-phenotype associations, and
phenotype-phenotype similarities. To accomplish this, we
artificially destroy informative interactions in the above
three networks and see what performances will turn out.
It is expected that both the mean rank ratios and the
AUC scores will be around 50%, together with very low

Figure 4 ROC curves of the leave-one-out cross-validation experiments. (A) Results for random controls. (B) Results for linkage intervals. (C)
Results for genome-wide scan. BF: the domainRBF approach (using Bayes factors as scores for candidate domains). R2: the ordinary non-Bayesian
linear regression approach (using R-square as scores for candidate domains). SG: shortest path with Gaussian kernel. DK: diffusion kernel.
Numbers in the parentheses are AUC scores of the corresponding ROC curves. The small domain-domain interaction network composed of the
PDB part of the DOMINE database is used to obtain the results.
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precisions. With this understanding, we perform three
permutation experiments: 1) shuffling interactions
among domains while fixing the node degree (number of
direct neighbours) distribution of the entire interaction
network, 2) shuffling interactions among domain-phenotype associations while fixing the number of associated
domains for each of the phenotypes, and 3) shuffling the
phenotype-phenotype similarity while fixing the distribution of phenotype similarities, respectively. Then we
repeat the leave-one-out cross-validation experiments
using the shuffled networks, which contain no informative interactions among domains, among domain and
phenotypes, or among phenotypes, respectively. As
shown in Figure 5, the results obtained are generally
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consistent with our expectation in that AUC scores are
all around 50%. We therefore conclude that the successful prioritization of candidate domains is indeed due to
the informative interactions among domains that are
included in the domain-domain interaction network.
Effects of different domain-domain interaction networks

We notice that the two compiled domain-domain interaction networks have different properties. For example,
the average degree of the smaller network that includes
only PDB entries is 2.32, while that of the larger network that includes predicted interactions from both
DOMINE and InterDom is 17.77. It is possible that
many predicted interactions may actually be noise and
thus negatively affect the prioritization of disease

Figure 5 ROC curves of the leave-one-out cross-validation experiments on shuffled data. (A) Results for random controls with domaindomain interactions shuffled. (B) Results for linkage intervals with domain-domain interactions shuffled. (C) Results for genome-wide scan with
domain-domain interactions shuffled. (D) Results for random controls with known domain-phenotype associations shuffled. (E) Results for linkage
intervals with known domain-phenotype associations shuffled. (F) Results for genome-wide scan with known domain-phenotype associations
shuffled. (G) Results for random controls with phenotype similarity profiles shuffled. (H) Results for linkage intervals with phenotype similarity
profiles shuffled. (I) Results for genome-wide scan with phenotype similarity profiles shuffled. The small domain-domain interaction network
composed of the PDB part of the DOMINE database and the diffusion kernel are used to obtain the results.
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domains. Hence, it is necessary to validate the robustness of the proposed approaches to the underlying
domain-domain interactions. For this purpose, we
implement the same validation process based on the
large compiled domain-domain interaction network that
is composed of all interactions in the DOMINE database
and high-confidence interactions in the InterDom database. Results are presented in Table 2, from which we
can see that the performances of the domainRBF
approach using the large domain-domain interaction
network that includes the entire DOMINE database and
the high-confidence interactions in the InterDom database are generally somewhat inferior to those using the
PDB part of the DOMINE database. For instance, when
using the domainRBF approach, the disparity of precisions, mean rank ratios and AUCs are all within the
scope of 10 percent. We then conjecture from these
results that the proposed domainRBF approach is quite
robust to the possible noise in the domain-domain
interaction network.
Effects of parameters in the distance measures

We further notice that the parameter b in the shortest
path measure with Gaussian kernel and the parameter g
in the diffusion kernel are free parameters that need to
be pre-determined (see Materials and Methods for
details). In the above cross-validation experiments we
set these parameters as 1 and 0.05, respectively, for simplicity. However, it is necessary to show whether the
prioritization methods are sensitive to these parameters.
For this purpose, we select several values across the
range of these parameters, perform the cross-validation
experiments, and see how the results change accordingly. We take the prioritization results using the
domainRBF approach against random controls (in Table
1) as an example to illustrate the influence of b. Since
this parameter ranges from 0 to +∞, we perform a grid
search of this parameter by changing it from 0.1 to 10
with step 0.1 and see the effect, as reflected in the
change of precision, mean rank ratio, and AUC score as
shown in Figure 6(A). From the curve we can see that

when b changes from 0.1 to 1, there is an obvious
upward climb for the three criteria, while after the point
b = 1.0 (precision = 26.56%, mean rank ratio = 11.99%,
and AUC score = 88.80%), the values in the curve
becomes fairly stable. Even so, we find that the peak
performance is obtained at b = 3.7 (precision = 28.89%,
mean rank ratio = 10.67%, and AUC score = 90.20%),
and the worst performance is obtained at b = 0.1 (precision = 18.01%, mean rank ratio = 19.23%, and AUC
score = 81.63%). From these results, we conclude that
the prioritization methods are not sensitive to this free
parameter when b is greater than 1. Similarly, we find
that the prioritization methods are not sensitive to the
free parameter g when it is smaller than 0.15 (data not
shown). The corresponding changes in precision, mean
rank ratio, and AUC score are shown in Figure 6(B).
We find that the peak performance is obtained at g =
0.03 (precision = 29.55%, mean rank ratio = 10.61%, and
AUC score = 90.16%), and the worst performance is
obtained at g = 0.93 (precision = 24.86%, mean rank
ratio = 13.34%, and AUC score = 87.46%). From the
results, we can see that the proposed approach is quite
robust when b in the shortest path with Gaussian kernel
is greater than 1 or when g in the diffusion kernel is
smaller than 0.15.
Effects of parameters in the domainRBF approach

Besides the two parameters in the distance measures,
there are also four parameters in the domainRBF
approach that need to be pre-determined, namely μ0 ,
s12, n0, and s02, all of which are included in the priors
of the domainRBF approach (see Materials and Methods
for details). In the real implementation we set μ0 = 0, n0
= 0, and s02 = 0, for the reason explained in the literature [44], and we set s12 = 1, for simplicity. Therefore,
we only need to test the robustness of the approach
when different values of s12 are used. To achieve this
objective, we set s12 as 0.001, 0.01, 0.1, 1, 10, and 100,
respectively, and we apply the approach to the same
cross validation process. We list the results in Table 3,
which shows that when s 1 2 is smaller than 1, the

Table 2 Results of leave-one-out cross-validation experiments on the large network.

Precision

Random Control (%)

Linkage Interval (%)

R2

BF

R2

BF

Genome-wide Scan (%)
R2

BF

SG

14.24 (0.37)

18.64 (0.66)

18.54

21.23

2.17

2.35

DK

16.80 (0.36)

22.32 (0.60)

17.36

27.56

2.42

3.47

Mean Rank Ratio

SG

27.27 (0.07)

19.59 (0.09)

21.89

18.07

26.53

18.79

AUC

DK
SG

26.07 (0.11)
73.41 (0.07)

14.96 (0.07)
81.15 (0.09)

20.21
78.57

14.12
81.76

25.34
73.38

14.11
81.09

DK

74.61 (0.11)

85.82 (0.07)

82.36

86.68

74.55

85.72

The large network indicates the domain-domain interaction network that is composed of the entire DOMINE database and high-confidence interactions in the
InterDom database. R2 denotes the ordinary non-Bayesian linear regression approach (using R-square as scores for candidate domains). BF denotes the
domainRBF approach (using Bayes factors as scores for candidate domains). SG denotes shortest path with Gaussian kernel. DK denotes diffusion kernel. Results
for random controls are mean (standard deviation) of 10 validation runs.
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Figure 6 Effects of parameters on distance measures. (A) Influence of b (from 0.1 to 10 with step 0.1) on shortest path with Gaussian kernel.
(B) Influence of g (from 0.01 to 1 with step 0.01) on diffusion kernel. The small domain-domain interaction network composed of the PDB part
of the DOMINE database is used to obtain the results.

domainRBF approach is quite robust to the change of
s12, with the change of precision within 1.12%, change
of mean rank ratios within 0.53%, and change of AUC
scores within 0.54%. On the other hand, when s12 is larger than 1, the decrease in performances becomes
slightly conspicuous, but remains within the scope of
3.04% for precisions, 2.22% for mean rank ratios and
1.77% for AUC scores. Hence we can see that our
domainRBF approach is generally robust to the change
of parameters.

Effects of seed domain-disease associations

In order to test the influence of the size of seed, or
known associations on the prioritization results, we
select at random 100%, 90%, 80%, 70%, 60%, and 50% of
the original seed associations, respectively, and we
repeat the leave-one-out validation processes. We only
calculate the performance using the domainRBF
approach based on diffusion kernel measure, and we
choose the PDB part of the DOMINE database as the
domain-domain interaction network. Results show that

Table 3 Effects of parameters based on leave-one-out cross-validation experiments.
Criteria

s 12

Random Control (%)

Linkage Interval (%)

Genome-wide Scan (%)

Precision

0.001

28.87 (0.70)

31.49

4.41

0.01

29.02 (1.17)

31.77

4.78

0.1

29.39 (0.60)

31.36

5.07

1

28.67 (0.72)

31.20

5.53

10

27.76 (0.62)

29.73

5.35

100

28.59 (1.18)

28.16

5.35

0.001

10.23 (0.07)

9.83

9.38

0.01

10.25 (0.11)

9.98

9.41

0.1

10.41 (0.07)

9.49

9.54

1

10.75 (0.09)

9.73

9.91

10

11.14 (0.10)

10.92

10.27

100

12.08 (0.10)

11.95

11.24

Mean Rank Ratio

AUC

0.001

90.58 (0.10)

90.14

90.55

0.01
0.1

90.56 (0.14)
90.40 (0.10)

90.40
90.22

90.61
90.40

1

90.04 (0.11)

90.18

90.11

10

89.69 (0.10)

89.23

89.86

100

88.74 (0.14)

88.41

88.98

The small domain-domain interaction network composed of the PDB part of the DOMINE database and the diffusion kernel are used to obtain the results. Results
for random controls are mean (standard deviation) of 10 validation runs.
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with the percentage of seed associations decreases from
100% to 50%, performance also slightly decreases in
terms of precision, mean rank ratio and AUC score,
despite some exceptions (see Table 4). For example, in
the cross-validation for random controls, the changes of
precisions are no more than 2.99%, the changes of mean
rank ratios are no more than 2.72%, and the changes of
AUC scores are no more than 2.73%. In the cross-validation for linkage intervals, the changes of precisions
are no more than 2.73%, the changes of mean rank
ratios are no more than 0.75%, and the changes of AUC
scores are no more than 0.78%. In the cross-validation
for genome-wide scan, the changes of precisions are no
more than 1.95%, the changes of mean rank ratios are
no more than 1.04%, and the changes of AUC scores
are no more than 0.95%. From these results, we conclude that the prioritization methods are not sensitive to
the size of seed associations in our problem.
In order to study how known domain-disease associations for other diseases contribute to the inference of
domains that are associated with the query disease, we
keep 10%, 20%, 30%, 40%, and 50% disease phenotypes
that have the highest similarity scores to the query disease, respectively, and we repeat the leave-one-out validation processes, using the diffusion kernel measure and
the small domain-domain interaction network that is
composed of the PDB part of the DOMINE database.
Results (Table 5) show that our method is robust in this
experiment, in the sense that the values of the three
evaluation criteria do not change significantly. For
example, in the cross-validation for random controls,
the changes of precisions are no more than 6.64%, the
changes of mean rank ratios are no more than 1.15%,

and the changes of AUC scores are no more than
1.20%. However, we also notice that the performance of
our approach tends to drop when more phenotypes
with lower similarity scores are included. For example,
in the experiment, our approach achieves the highest
performance when keeping only 10% phenotypes which
have the highest similarity scores to the query phenotype and the lowest performance when keeping 50% of
the most similar phenotypes, although the drop in performance is small. We also repeat the above analysis
using the large domain-domain interaction network that
includes the entire DOMINE database and the highconfidence part of the InterDom database, and we
obtain similar results [Additional file 2: Supplemental
Table S1]. From these results, we conclude that seed
domain-disease associations in which the diseases have
high phenotype similarity scores with the query disease
have main contributions in the prioritization procedure.
Ab initio inference of domain-disease and gene-disease
associations

Above we have used several large scale leave-one-out
cross-validation experiments to evaluate the performance and robustness of the proposed domainRBF
approach. However, it might be argued that a disease
may be associated with more than one domain and that,
consequently, the inclusion of domains already known
to be associated with the query disease in the calculation
of the domain proximity profile may ease the identification of novel associations. Following this line of reasoning, we demonstrate the capability of the proposed
domainRBF approach in the prediction of novel associations for query diseasesby performing the following ab

Table 4 Effects of seed domain-disease associations based on leave-one-out cross-validation experiments.
Criteria

Cutoff

Random Control (%)

Linkage Interval (%)

Genome-wide Scan (%)

Precision

90%

28.28 (0.42)

33.45 (1.57)

5.34 (0.33)

80%

27.42 (0.76)

32.06 (1.44)

4.79 (0.47)

70%
60%

27.43 (1.06)
25.68 (1.04)

29.59 (0.93)
30.11 (1.10)

3.97 (0.74)
3.58 (0.58)

50%

25.85 (0.73)

28.47 (0.89)

5.35 (1.22)

90%

10.90 (0.78)

8.98 (0.64)

10.16 (0.81)

80%

11.23 (0.84)

9.37 (0.92)

10.38 (1.02)

70%

11.68 (1.21)

10.09 (1.05)

10.61 (0.69)

60%

12.37 (0.97)

9.21 (1.01)

10.76 (0.80)

50%

13.47 (0.55)

9.72 (0.98)

10.95 (0.78)

90%
80%

89.92 (0.30)
89.60 (0.22)

90.83 (0.58)
90.26 (0.43)

89.87 (0.61)
89.66 (0.29)

70%

89.15 (0.17)

89.40 (0.64)

89.46 (0.48)

60%

88.48 (0.59)

90.01 (0.51)

89.32 (0.34)

50%

87.31 (0.28)

89.89 (0.46)

89.16 (0.75)

Mean Rank Ratio

AUC

The small domain-domain interaction network composed of the PDB part of the DOMINE database and the diffusion kernel are used to obtain the results. Results
for random controls are mean (standard deviation) of 10 validation runs.

Zhang et al. BMC Systems Biology 2011, 5:55
http://www.biomedcentral.com/1752-0509/5/55

Page 14 of 21

Table 5 Contributions of seed domain-disease associations based on leave-one-out cross-validation experiments.
Criteria

Cutoff

Random Control (%)

Linkage Interval (%)

Genome-wide Scan (%)

Precision

10%

37.82 (0.72)

42.29

8.16

20%

34.55 (1.03)

38.39

8.63

30%

32.85 (0.77)

37.52

7.79

40%

32.78 (0.97)

36.98

7.79

50%

31.18 (0.62)

34.50

6.16

10%

8.83 (0.06)

7.87

7.96

20%

8.80 (0.07)

7.92

7.95

30%
40%

9.23 (0.03)
9.64 (0.07)

8.47
8.61

8.33
8.74

50%

9.98 (0.06)

8.86

9.09

Mean Rank Ratio

AUC

10%

92.14 (0.12)

94.08

91.75

20%

92.16 (0.10)

93.91

91.83

30%

91.71 (0.10)

93.46

91.42

40%

91.33 (0.08)

92.63

91.08

50%

90.94 (0.06)

92.30

90.66

The small domain-domain interaction network composed of the PDB part of the DOMINE database and the diffusion kernel are used to obtain the results. Results
for random controls are mean (standard deviation) of 10 validation runs.

initio inference experiments. For each query disease, we
calculate domain proximity profiles with the exclusion
of all domains that are known to be associated with the
disease (i.e., as if genetic bases of the disease were completely unknown), apply the domainRBF method to
score candidate domains, and then prioritize the candidates. We again perform random control, linkage interval, and genome-wide validation experiments and
evaluate the performance of our approach in terms of
precision, mean rank ratio, and AUC scores. We perform this ab initio inference using the large network
that is composed of entire interactions in DOMINE and
high-confidence interactions in InterDom (with diffusion
kernel), and we summarize the results in Table 6.
In comparison with the results in Table 2, we find that
the performance of the domainRBF approach slightly
drops (less than 4%). For example, for the random control validation, the precision is almost the same, the
mean rank ratio drops from 14.96% to 17.34%, and the
AUC score from 85.82% to 83.43%. For the linkage
interval validation, the precision drops from 27.56% to
24.39%, the mean rank ratio from 14.12% to 17.07%,
and the AUC score from 86.68% to 84.62%. For the genome-wide validation, the precision even increases
slightly from 3.47% to 3.90%, while the mean rank ratio
drops from 14.11% to 16.45% and the AUC score from
85.72% to 83.27%. In other words, for a query disease of

interest, our approach is capable of inferring novel associations between domains and the disease without prior
knowledge about genetic bases of the disease. This characteristic of our approach is of great importance,
because the genetic bases for about half of the diseases
in the OMIM database are still unknown [47].
We also study the contribution of seed domain-disease
associations by keeping a fraction of disease phenotypes
that have the highest similarity scores to the query disease and repeating ab initio prediction experiments. We
observe from the results [Additional file 2: Supplemental
Tables 2 and 3] that seed domain-disease associations in
which the diseases have high phenotype similarity scores
with the query disease have main contributions in the
prioritization procedure. We further study whether the
ab initio prediction tends to give higher ranks to
domains that occur more frequently in human proteins.
We merge the frequency of occurrence of domains in
all human proteins into 11 bins (0-10, 11-20, 21-30, 3140. 41-50, 51-60, 61-70, 71-80, 81-90. 91-100, 101 and
above), and we look at how ranks of domains that are
known to be associated with diseases distribute in different bins. From the results [Additional file 1: Supplemental Figure S2], we see that the median of mean ranks of
such domains do not show much change for different
bins, indicating that our method is not biased towards
common domains.

Table 6 Ab initio inference of domain-disease associations.
Random Control (%)

Linkage Interval (%)

Genome-wide Scan (%)

Precision

22.11 (0.45)

24.39

3.90

Mean Rank Ratio

17.34 (0.07)

17.07

16.45

AUC

83.43 (0.07)

84.62

83.27
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Inspired by the success of ab initio inference of
domains and diseases, we further propose the following
application of the proposed domainRBF approach in the
inference of genes that are associated with diseases, by
combining predicted domain-disease associations and
known domain-protein relations. As shown in Figure 7,
given a query disease and a gene whose products (proteins) are usually composed of several protein domains,
we look at corresponding Bayes factors of these domains
and define an association score that measures the
strength of association between the gene and the disease
as the maximum among these Bayes factors. Then,
given a set of candidate genes, we are able to obtain
association scores for the genes and further rank the
genes according to their scores.
We validate our gene prioritization approach using
known gene-disease associations extracted from the BioMart database [48,49]. After ruling out diseases that do
not exist in our phenotype similarity network and genes
whose products do not have domain annotation, we
obtain 2,847 associations between 1,737 genes and 1,875
diseases. We then prioritize each of these genes that are
known to be associated with some diseases (disease
genes) against a total of 14,944 genes whose products
have domain annotations. Results show that in 207 out
of the 2,847 associations, the known disease genes rank
first in the candidate list of 14,944 genes, obtaining a
precision of 7.27%, as well as a fold enrichment of 1,087
(It should be noted that fold enrichment is defined in
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existing literature [32] as follows: for a method that is
able to rank known disease genes among the top a% of
all candidates in b% validation runs, the fold enrichment
is b/a on average). In other words, our domainRBF
approach can also be effectively used as an intermediate
step to infer associations between genes and diseases.
Genome-wide evidence of associations between domains
and common human diseases

The identification of susceptible single nucleotide polymorphisms (SNPs) conferring risk for common human
diseases is one of the main tasks of genome-wide association studies (GWAS). Since the study that identified
the association of complement factor H (CFH) with agerelated macular degeneration (AMD) in 2005, over 450
GWAS have been performed and more than 2,000 susceptible SNPs or genetic loci have been reported [50].
With these resources, it is of interest to to determine
the extent to which the genome-wide ab initio inference
of associations between domains and diseases are consistent with these GWAS results.
Given a disease of interest, we collect from SNPedia
[51,52] or other relevant literatures a list of reported
susceptible SNPs, and we see how many of these SNPs
appear within 5 Mbp of the domains that are ranked in
the top 10 in our genome-wide ab initio inference,
which uses all domains in the domain-domain interaction network as candidates. We further implement the
following permutation test to check whether the number

Figure 7 Scheme of inferring gene-disease associations from domain-disease associations.
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of such susceptible SNPs is significantly enriched within
these regions, as
1. Count the number of reported SNPs that appear
within 5 Mbp of domains that are ranked among the
top 10 in the genome-wide ab initio inference.
Record this number as N0.
2. For the i-th permutation, select 10 domains at
random from all domains in the genome-wide ab
initio inference. Count the number of reported SNPs
that appear within 5 Mbp of these domains. Record
this number as Ni.
3. Repeat the above random selection M times (M =
10,000 in our study). Count the number of times
that N i (i = 1,...,N) is greater than or equal to N 0 .
Record this number as m.
4. Calculate a p-value as p = m/M.
The null hypothesis in the above permutation test is
that the number of the reported susceptible SNPs within
5 Mbp regions of the high ranking domains (top 10) is
not different from that of randomly selected domains.
Therefore, a small p-value indicates that the reported
susceptible SNPs tend to be closer to the high ranking
domains. In other words, high ranking domains are
more likely to be associated with the disease under
investigation.
We then select four disease examples (Type 1 diabetes, Type 2 diabetes, Crohn’s disease, and Breast cancer), apply the above permutation test method to these
diseases, and analyze the results in detail. We choose
these four diseases because they are common and have
GWAS results available. It has been shown that diabetes
had affected 2.8% of the population worldwide by 2000
[53], with type 2 diabetes as the most common form of
this disease [54]. It is also known that Crohn’s disease
affects 0.2% to 0.1% people within the UK [55], and that
breast cancer is the most common type of non-skin cancer in women and the fifth most common cause of cancer death [56,57].
Type 1 Diabetes

Type 1 diabetes, formerly called juvenile diabetes or
insulin-dependent diabetes, is a condition in which pancreatic b cell destruction usually leads to absolute insulin deficiency [58]. The genetic susceptibility of Type 1
diabetes is strongly associated with HLA-DQ and DR on
chromosome 6, but genetic factors on other chromosomes such as the insulin gene on chromosome 11 and
the cytotoxic T-lymphocyte antigen gene on chromosome 2 may modulate disease risk [59]. In our study, we
compile from SNPedia 48 reported susceptible SNPs,
and 25 of them are found to be within 5Mbp regions of
6 domains (i.e., NACHT, Recep_L_domain, Collagen,
HNF-1A_C, CARD, and FGF) that are ranked among
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the top 10. We present the detailed list of these domains
and SNPs [Additional file 2: Supplemental Table S4]. In
summary, we observe 3 times that a susceptible SNP
locates inside a domain (once in each of Recep_L_domain, Collagen, and HNF-1A_C, respectively), 15 times
that a susceptible SNP locates within 1 Mbp upstream
or downstream of a domain, and 44 times that a susceptible SNP locates within 5 Mbp region of a domain. The
permutation test, as described above, yields a p-value of
0.0313, which is smaller than 0.05. From these results
we conjecture that domains ranked among the top 10
do, indeed, tend to be closer to, or even include, known
susceptible SNPs for this disease.
In addition, we also examine the 4 domains that are
not close to susceptible SNPs reported by GWAS. For
domain HNF-1B_C (PF04812), we notice that Urhammer et al. [60] have pointed out that mutations and
polymorphisms in HNF-1 cause the type 3 form of
maturity-onset diabetes of the young (MODY3), and for
domain HNF-1_N (PF04814), mutations and the common polymorphism Ala/Val in position 98 of HNF-1
also cause MODY3. It is known that MODY3 is a kind
of monogenic diabetes, which is different from type 1
diabetes that involves more complex combinations of
causes involving multiple genes and environmental factors (i.e., polygenic). However, most commonly MODY3
acts like a very mild version of type 1 diabetes, with
continued partial insulin production and normal insulin
sensitivity [61]. Therefore, domain HNF-1B_C
(PF04812) and domain HNF-1_N (PF04814), which are
highly ranked in terms of our approach, may also be
closer to, even include, known susceptible SNPs for this
disease.
Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset diabetes or
noninsulin-dependent diabetes, is the most common
form of diabetes. It usually begins with insulin resistance, a condition in which fat, muscle, and liver cells
do not use insulin properly [62]. Numerous SNPs have
been associated with (slightly) increased risk for type-2
diabetes [63,64], but they only marginally improve the
odds of predicting whether an individual will get type-2
diabetes based on the traditional clinical characteristics
combining age, sex and weight [65]. In our study, we
compile from SNPedia and reference [64] a total of 53
reported susceptible SNPs, and 24 of them are found to
be within 5 Mbp regions of 7 domains (i.e., HNF-1B_C,
IF_tail, Sulfatase, Collagen, Alk_phosphatase, Pkinase_Tyr, and FGF) that are ranked among top 10. We present the detailed list of these domains and SNPs
[Additional file 2: Supplemental Table S5]. In summary,
we observe 47 times that a susceptible SNP locates
within 1 Mbp upstream or downstream of a domain,
and 102 times that a susceptible SNP locates within 5
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Mbp region of a domain. The permutation test yields a
p-value of 0.0363, which is smaller than 0.05. From
these results we conjecture that domains ranked among
the top 10 do, indeed, tend to be closer to known susceptible SNPs for this disease.
In addition, we also examine the 3 domains that are
not close to susceptible SNPs reported by GWAS. We
notice that both domains HNF-1A_C (PF04813) and
HNF-1_N (PF04814) contain mutations that may cause
the type 3 form of maturity-onset diabetes of the young
(MODY3), as pointed out by Urhammer et al. [60].
Although type 2 diabetes may share some characteristics
in common with MODY3, no direct evidence has yet
been found to demonstrate that these two domains
cause type 2 diabetes.

Collagen, NACHT, and Recep_L_domain) that are
ranked among the top 10. We present the detailed list
of these domains and SNPs [Additional file 2: Supplemental Table S7]. In summary, we observe 6 times that
a susceptible SNP locates inside a domain (all in Pkinase_Tyr), 21 times that a susceptible SNP locates within
1 Mbp upstream or downstream of a domain, and 80
times that a susceptible SNP locates within 5 Mbp
region of a domain. The permutation test yields a pvalue of 0.0159, which is smaller than 0.05. From these
results we conjecture that domains ranked among the
top 10 do, indeed, tend to be closer to, or even include,
known susceptible SNPs for this disease.

Crohn’s Disease

For each of the four diseases examples, we further evaluate the contribution of seed domain-disease associations by keeping 10%, 20%, 30%, 40%, and 50% disease
phenotypes that have the highest similarity scores to the
query disease, obtaining a rank list of all domains, and
then using the permutation test to check whether the
number of known susceptible SNPs is still significantly
enriched around the top ranking domains. As shown in
[Additional file 2: Supplemental Table S8], we find that
all resulting p-values are smaller than 0.05, and are also
numerically close to those obtained using all phenotypes. We therefore conjecture that our approach is
robust to the seed domain-disease associations in the
inference for these disease examples.

Crohn’s disease, a chronic inflammatory disorder of the
gastrointestinal tract, is thought to result from the combination of effect of environmental factors and genetic
predisposition [66,67]. Recently, genome-wide association studies have made notable progress in the study of
this disease, with the number of confirmed associated
loci increasing from two to more than ten [68,69]. In
our study, we compile from SNPedia 36 reported susceptible SNPs, and 29 of them are found to be within 5
Mbp regions of 8 domains (i.e., Sulfatase, NACHT, Collagen, Crystall, Pkinase_Tyr, CARD, Gla, and Hormone_1) that are ranked among top 10. We present the
detailed list of these domains and SNPs [Additional file
2: Supplemental Table S6]. In summary, we observe 5
times that a susceptible SNP locates inside a domain (3
times in NACHT and 2 times in Pkinase_Tyr), 21 times
that a susceptible SNP locates within 1 Mbp upstream
or downstream of a domain, and 49 times that a susceptible SNP locates within 5 Mbp region of a domain. The
permutation test yields a p-value of 0.0029, which is far
smaller than 0.05. From these results we conjecture that
domains ranked among the top 10 do, indeed, tend to
be closer to, or even include, known susceptible SNPs
for this disease.
Breast Cancer

Breast cancer, the most common malignancy in women
in the Western world [70], exhibits a characteristic of
familial clustering [70,71]. Although little is known currently to explain the familial clustering of breast cancer,
a large amount of susceptible genes and SNPs of this
disease have been recently reported, including the wellknown high breast cancer risk in BRCA1 and BRCA2
mutation carriers as well as the risk for breast cancer in
certain rare syndromes caused by mutations in TP53,
STK11, PTEN, CDH1, NF1 or NBN [70]. In our study,
we compile from SNPedia 60 reported susceptible SNPs,
and 38 of them are found to be within 5 Mbp regions
of 7 domains (i.e., Sulfatase, Pkinase_Tyr, Crystall, FGF,

Contributions of seed domain-disease associations in the
analysis of the four diseases

A predicted landscape of domain-disease associations

With the above validation results demonstrating the
possibility of recovering the associations between protein domains and disease phenotypes, we further apply
the domainRBF approach to all available protein
domains and human disease phenotypes and predict a
genome-wide landscape of the associations between protein domains and human disease phenotypes. There are
a total of 5,080 phenotypes in the phenotype similarity
network and 5,490 protein domains in the domaindomain interaction network (the union of the entire
DOMINE and InterDom network). For each phenotype,
we perform a prioritization of all domains with the use
of the domainRBF approach (using the diffusion kernel
measure). The prioritization results, together with a
freely accessible web interface, are provided at http://
bioinfo.au.tsinghua.edu.cn/domainRBF/domain. All
domains on the webpage are linked to the DOMINE
database and the InterDom database, from which further
information can be obtained.
On the basis of the above prioritization results, we
aggregate the Bayes factors between all the 5,490
domains and 1,145 phenotypes, and obtain a matrix of
altogether 6,286,050 elements. Here we first make a log

Zhang et al. BMC Systems Biology 2011, 5:55
http://www.biomedcentral.com/1752-0509/5/55

(base 10) transform of original matrix, and then implement clustering while removing the rows in which the
values are all smaller than 0.1. Since phenotypes clustered together generally have similar molecular basis, or
share significant genetic overlaps [32], we implement a
two-way hierarchical clustering [72], to identify interesting areas where large values of Bayes factors are highly
enriched. The clustering result is demonstrated in the
form of a heat map, as shown in Figure 8(A). We then
manually inspect and annotate each of the phenotype
clusters with one of the 22 disorder classes based on the
physiological system affected [73]. Through clustering,
many highly scored blocks or regions are formed in the
heat map, each of which represents a set of functionally
related domains implicated in a set of genetically overlapping phenotypes [32]. Specifically, we take the region
in the pink circle as an example, which is enlarged in
Figure 8(B). Phenotypes in the region selected are
enriched with diseases related to the muscle system, and
domains are also conjectured to share similar functions
with adjacent domains in the same region.
We further apply the above prioritization method to
all human disease phenotypes and obtain a landscape of
gene-phenotype associations that include 5,080 disease
phenotypes and 14,944 human genes. The prioritization
results, together with a freely accessible web interface,
are provided at http://bioinfo.au.tsinghua.edu.cn/
domainRBF/gene/. All genes on the webpage are linked
to the Ensembl database [74], from which further information can be obtained.

Discussion and Conclusions
In this paper, we studied the problem of identifying
domains that are associated with human inherited diseases under a prioritization framework. We proposed an
approach called domainRBF from the perspective of
Bayesian regression, verified its superior performance
through three large-scale cross-validation experiments,
and demonstrated the robustness of this approach via a
series of permutation tests. We further proposed to perform ab initio inference of domain-disease associations
and gene-disease associations. Finally, we calculated a
landscape between 5,490 protein domains and 5,080 disease phenotypes.
In comparison with previous studies that rely on phenotype similarity and protein-protein interaction data to
infer gene-disease associations [32], our approach can
achieve higher resolution in pinpointing susceptibility
functional units in the genome, essentially because a
domain is only a fraction of a protein and is typically
small in size (ranging between 40 and 700 residues [75]
with an average of approximately 100 residues [76]).
Moreover, as demonstrated in the Results section, our
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approach can also be used as an intermediate step in
the inference of gene-disease associations.
However, our method has the following limitations.
First, our method can only be applied to diseases that
are included in phenotype similarity data and domains
that are included in domain interaction data. In the case
of phenotype similarity, a possible solution would
involve the development of a visualization and annotation system such as the one in [77] that can associate a
new disease to a standard vocabulary and then calculate
similarities for the new disease. In the case of domain
interaction data, a possible solution would involve the
development of effective computational methods to predict domain-domain interactions.
Second, our method currently only considers conjugate priors in the Bayesian regression model. Although
such formulation results in analytic solutions and thus
alleviates the computational burden in the calculation of
Bayes factors, it is known that the specification of prior
is intrinsically complicated and subjective [44]. The
main consideration is that the posterior mean and variance should not depend on the units in which the disease similarities are measured and should also be
invariant to the shift of the response variable. To meet
these requirements, the use of the Jeffreys prior [78]
could be considered, and a Markov chain Monte Carlo
(MCMC) approach could be adopted for the calculation
of the marginal likelihood.
Our approach can be further studied from the following aspects. First, in addition to the domain-domain
interaction network, information such as annotations of
Pfam domains in the Gene Ontology (GO) can also provide a means for calculating similarities between
domains. Recently, methods for calculating semantic
similarities between GO terms have been packed into
user-friendly software [79]. It is therefore possible to
calculate pair-wise semantic similarities between every
two domains and then use this similarity profile with
our domainRBF model to infer associations between
domains and human inherited diseases.
Second, it is conceptually straightforward to extend
the domainRBF model to infer interactive effects of multiple domains on a query disease. For example, given a
query disease and a set of candidate domains, we can
enumerate all two-way combinations of the domains
and then use the DomainRBF model to infer possible
associations between the disease and interactions of two
domains. Nevertheless, such brute force method is computationally intensive and not quite feasible in application to the study of three-way or even higher order
interactive effects of candidate domains.
Third, with the accumulation of publicly available data
in genome-wide association (GWA) studies, we can
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Figure 8 Modular organization of the predicted landscape of human disease phenotypes. (A) Two-way hierarchical clustering heat map
for the landscape of domain-phenotype associations. (B) Zoomed-in plot of the pink circle region in the heat map, involving 17 muscular
diseases and 20 related protein domains.

consider the integration of our method and GWA studies. For example, given a disease of interest and a set
of candidate domains, we can prioritize the candidate
domains using our method and obtain the ranks of the

domains. On the other hand, given p-values of SNPs in
a GWA study, we can obtain the statistical significance
of candidate domains in the GWA study by combining
the p-values of SNPs located in the domains and then
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prioritize the candidates to obtain their ranks. With
these two ranks, we can resort to statistical methods,
such as the one described in [8], to obtain a single rank
for each candidate domain.

6.

Additional material

7.

Additional file 1: Supplemental Figures. Supplemental Figure S1
shows the results of a series of permutation test using the large domaindomain interaction network. Supplemental Figure S2 shows the mean
ranks for domains with different frequency of occurrence in human
proteins.
Additional file 2: Supplemental Tables. Supplemental Table S1 lists
contributions of seed domain-disease associations (leave-one-out crossvalidation experiments using the large domain-domain interaction
network). Supplemental Table S2 lists contributions of seed domaindisease associations (ab initio prediction experiments using the small
domain-domain interaction network). Supplemental Table S3 lists
contributions of seed domain-disease associations (ab initio prediction
experiments using the large domain-domain interaction network).
Supplemental Table S4 lists the genome-wide evidence of associations
between domains and type 1 diabetes. Supplemental Table S5 lists the
genome-wide evidence of associations between domains and type 2
diabetes. Supplemental Table S6 lists the genome-wide evidence of
associations between domains and Crohn’s disease. Supplemental Table
S7 lists the genome-wide evidence of associations between domains and
breast cancer. Supplemental Table S8 lists contributions of seed domaindisease associations in the analysis of the four disease examples.
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